Search

Search Constraints

You searched for: Author/Creator Lu, Yinying

Search Results

13. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Issue 7 (July 2021)